GlassScriptPhysician profile
Danielle Scampini
NPI 1003315706
$4,215.67
in general payments reported to CMS, 2019-2025
30 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $841 · 2023: $1,206 · 2024: $527 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939 · Travel and Lodging: $148 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.31 |
| Travel and Lodging | $148.03 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $653.76 | 2022-2025 | Urolift, Barrigel |
| Medtronic, INC. | $464.87 | 2022-2023 | Interstim |
| Janssen Biotech, INC. | $406.20 | 2023-2025 | Erleada |
| Sumitomo Pharma America, INC. | $397.00 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $299.27 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $213.44 | 2023-2025 | |
| Boston Scientific Corporation | $158.92 | 2023-2025 | Rezum Generator, Solyx Sis System |
| Merck Sharp & Dohme LLC | $150.38 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Axonics, INC. | $146.51 | 2022 | |
| Antares Pharma, INC. | $132.11 | 2024-2025 | Xyosted |
| Coloplast Corp | $128.92 | 2023 | Speedicath |
| Astellas Pharma US INC | $124.36 | 2021-2024 | Xtandi, Myrbetriq |
| 180 Medical, INC. | $102.67 | 2022-2025 | Gentlecath Glide |
| Convatec INC. | $101.11 | 2022-2024 | |
| Procept Biorobotics Corporation | $94.39 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $87.74 | 2025 | Eligard, Jatenzo |
| Amgen INC. | $70.48 | 2021 | |
| Srs Medical Systems, INC. | $68.77 | 2025 | Ct3000 Pro Base Unit, Urocuff-Dc Disposable, Single |
| Novartis Pharmaceuticals Corporation | $66.75 | 2025 | |
| Rochester Medical Corporation | $55.44 | 2022 | |
| Seagen INC. | $54.99 | 2025 | |
| Mission Pharmacal Company | $45.32 | 2022-2023 | Uribel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $28.62 | 2021 | |
| Myovant Sciences INC. | $27.30 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $24.42 | 2021 | |
| Dendreon Pharmaceuticals LLC | $24.33 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.20 | 2024 | Adstiladrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2022 | |
| Urovant Sciences INC | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Scampini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.